RespireRx Pharmaceuticals Inc (fka RSPI)

[gershfinance]

The IND has not yet been filed.

Per the prospectus dated today, "In July 2007, the FDA, upon review of the additional data, indicated that we may resume our previously approved clinical trials with CX717 in Alzheimer’s disease at all requested dose levels. During the third quarter of 2007, we intend to file an Investigational New Drug Application for CX717 with the FDA’s Division of Psychiatry Products to allow us to initiate a Phase IIb study evaluating CX717 for the treatment of ADHD."